Filing Flows › Standard Biotools (LAB) › Q2 2026 › vs Q1 2026
Standard Biotools (LAB) Q2 2026 vs Q1 2026 (quarter over quarter)
Standard Biotools's revenue fell $1.0M (-5%) from $21.1M in Q1 2026 to $20.1M in Q2 2026. The biggest changes: Product −$939K (-6%); Services and Other Revenue −$103K (-2%).
Standard Biotools, Q2 2026: revenue $20.1M (-8% year over year), operating margin -126.3%, net loss $26.8M, operating cash flow −$10.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $9.4M | $11.0M | −$1.6M | -15% |
| Instruments | $5.1M | $4.5M | $660K | +15% |
| Product | $14.5M | $15.5M | −$939K | -6% |
| Services and Other Revenue | $5.6M | $5.7M | −$103K | -2% |
| Revenue | $20.1M | $21.1M | −$1.0M | -5% |
| Net loss | $26.8M | −$127M | $154M | — |
| Costs & expenses | $46.9M | $161M | −$114M | -71% |
| Operating costs | $45.5M | $33.6M | $11.8M | +35% |
| Interest & other, net | $1.3M | −$140M | $141M | — |
| Income tax | $90K | $11K | $79K | +718% |
| Cost of revenue | $9.6M | $9.8M | −$269K | -3% |
| Research & development | $2.0M | $2.1M | −$141K | -7% |
| SG&A | $16.4M | $18.6M | −$2.2M | -12% |
| Other operating costs | $17.6M | $3.1M | $14.5M | +470% |
| Operating cash sources | $26.8M | −$127M | $154M | — |
| Depreciation & amortization | $1.3M | $1.4M | −$135K | -10% |
| Share-based compensation | $4.0M | $8.8M | −$4.8M | -54% |
| Working capital & other | $11.1M | −$184M | $195M | — |
| Cash used in operations | $10.3M | $46.6M | −$36.3M | -78% |
| Net loss absorbed | $26.8M | −$127M | $154M | — |
Questions
How much did Standard Biotools's revenue grow quarter over quarter in Q2 2026?
Standard Biotools's revenue fell $1.0M (-5%) from $21.1M in Q1 2026 to $20.1M in Q2 2026.
What drove Standard Biotools's revenue change in Q2 2026?
Product −$939K (-6%); Services and Other Revenue −$103K (-2%).